Advertisement

Topics

Abuse-Deterrent Opioids: Rexista To Test New FDA Leadership's Approach

14:46 EDT 30 Jun 2017 | SCRIP

Intellipharmaceutics seeks oral, intranasal and intravenous abuse-deterrence claims for Rexista (extended-release oxycodone) when it goes before an advisory committee July...

      

Related Stories

 

Original Article: Abuse-Deterrent Opioids: Rexista To Test New FDA Leadership's Approach

NEXT ARTICLE

More From BioPortfolio on "Abuse-Deterrent Opioids: Rexista To Test New FDA Leadership's Approach"

Advertisement
Quick Search
Advertisement
Advertisement